Observed and expected serious adverse event rates in randomised clinical trials for hypertension: an observational study comparing trials that do and do not focus on older people
Open Access
- 10 June 2021
- journal article
- research article
- Published by Elsevier BV in The Lancet Healthy Longevity
- Vol. 2 (7), e398-e406
- https://doi.org/10.1016/s2666-7568(21)00092-1
Abstract
No abstract availableFunding Information
- Wellcome Trust (201492/Z/16/Z, MR/S021949/1)
- Medical Research Council (201492/Z/16/Z, MR/S021949/1)
This publication has 30 references indexed in Scilit:
- Adverse drug reactions in special populations – the elderlyBritish Journal of Clinical Pharmacology, 2015
- Underrepresentation of Elderly People in Randomised Controlled Trials. The Example of Trials of 4 Widely Prescribed DrugsPLOS ONE, 2012
- Treatment of Hypertension in Patients 80 Years of Age or OlderThe New England Journal of Medicine, 2008
- Eligibility Criteria of Randomized Controlled Trials Published in High-Impact General Medical JournalsJAMA, 2007
- Randomized Controlled Trials: Do They Have External Validity for Patients With Multiple Comorbidities?Annals of Family Medicine, 2006
- Hypertension in Adults Across the Age SpectrumJAMA, 2005
- Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesThe Lancet, 2002
- Barriers to Participation in Randomised Controlled Trials: A Systematic ReviewJournal of Clinical Epidemiology, 1999
- The effect of age upon liver volume and apparent liver blood flow in healthy manHepatology, 1989